FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. *See* Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

(Print or Ty	pe Response	s)		,													
1. Name and Address of Reporting Person* Mann Brenda				2. Issuer Name and Ticker or Trading Symbol EYEGATE PHARMACEUTICALS INC [EYEG]								5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director X Officer (give title below) VP of Research & Development					
(Last) (First) (Middle) C/O EYEGATE PHARMACEUTICALS, INC., 271 WAVERLY OAKS ROAD, SUITE 108				3. Date of Earliest Transaction (Month/Day/Year) 12/07/2020							y/Year)		VP of Re	esearch & Do	evelopment		
(Street) WALTHAM, MA 02452				4. If Amendment, Date Original Filed(Month/Day/Year)							h/Day/Year)	6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person Form filed by More than One Reporting Person					
(City) (State) (Zip)				Table I - Non-Derivative Securities Acqui							Securities	ired, Disposed of, or Beneficially Owned					
1.Title of Security (Instr. 3)			2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, any (Month/Day/Ye		(Instr. 8)		(A) or Dis		Disposed	of (D)	5. Amount of Securities Beneficially Owned Follo Reported Transaction(s) (Instr. 3 and 4)		ollowing	6. Ownership Form: Direct (D)	7. Nature of Indirect Beneficial Ownership	
				(ivioliali Buy)		1 ()	Со	de	V	Amour	(A) or (D)	Price	(or Indirect (I) (Instr. 4)	(Instr. 4)
Common Stock 12/07		12/07/2020				F(1)			91	D	\$ 3.76	17,371		D			
Reminder:	Report on a s	separate line fo	or each class of secur	Deriva	ntive Secu	ıritie	es Acc	quire	Pers conta the f	ons whained i	no respo n this fo splays a of, or Ber	rm ar curre reficia	e not requently valid	ction of inf uired to res OMB conf	spond unle	ess	1474 (9-02)
1 Tid 6	2	2			uts, calls,			s, op						8. Price of	0 Nh	- £ 10	11 Notes
Security	Conversion or Exercise Price of Derivative Security		Execution Day Year) any	te, if Transaction Code Year) (Instr. 8)		on N o I S A (A I I o o (I	Number a		6. Date Exercisable and Expiration Date (Month/Day/Year)		Am Uno Sec	Citle and count of derlying urities str. 3 and		9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s (Instr. 4)	Owners Form of Derivat Securit Direct of Or India	Beneficia Ownershi y: (Instr. 4)	
					Code	V ((A)	(D)	Date Exer	cisable	Expiratio Date	n Titl	Amount or Number of Shares				

Reporting Owners

	Relationships						
Reporting Owner Name / Address		10% Owner	Officer	Other			
Mann Brenda C/O EYEGATE PHARMACEUTICALS, INC. 271 WAVERLY OAKS ROAD, SUITE 108 WALTHAM, MA 02452			VP of Research & Development				

Signatures

/s/ Sarah Romano, Attorney-in-Fact*	12/08/2020		
**Signature of Reporting Person	Date		

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Sale of shares to cover taxes due on restricted stock that vested on 12/01/2020.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.